Advertisement

Top 10 Clinical Review

Feature

Top 10 HIV Clinical Developments of 2014

December 15, 2014

David Alain Wohl, M.D.

David Alain Wohl, M.D.

A year ago we were rubbing our hands in delight at shiny new integrase inhibitors and the first members of a merciful new generation of HCV therapies. Now, these seem like last year's holiday gifts -- first glee-inducing, then old hat.

Elvitegravir (Vitekta) and dolutegravir (Tivicay, DTG) have snipped their way into our HIV treatment prescribing gene, and along with raltegravir (Isentress) form a troika that dominates the U.S. Department of Health and Human Services HIV treatment guidelines.

Back at the end of 2013, we were struggling to spell the new HCV drugs sofosbuvir (Sovaldi) and simeprevir (Olysio). Today, the former has been glommed into a single-tablet wonder pill (sofosbuvir/ledipasvir, a.k.a. Harvoni) while the latter has to vie for relevance.

The past year also saw pre-exposure prophylaxis (PrEP) start to get the love that had long been withheld, but also the dimming of our hopes for eradicating HIV. Oh, and that Affordable Care Act thing got millions of people health insurance -- but not without some kicking and screaming.

These and other top stories make my list for 2014. It all happened so fast. Indeed, time flies like an arrow -- and, as you know, fruit flies like a banana.

Table of Contents

David Alain Wohl, M.D., is an associate professor of medicine in the Division of Infectious Diseases at the University of North Carolina and site leader of the University of North Carolina AIDS Clinical Trials Unit at Chapel Hill.


Copyright © 2014 Remedy Health Media, LLC. All rights reserved.



This article was provided by TheBodyPRO.com.
 

 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.